A Randomized Clinical Trial Comparing Breakfast and Bedtime Administration of Insulin Glargine in Children and Adolescents with Type 1 Diabetes by Gökşen Şimşek, Damla et al.
J Clin Res Ped Endo 2008;1(1):15–20
DOI: 10.4008/jcrpe.v1i1.10 
© 2008 Journal of Turkish Pediatric Endocrinology and Diabetes Society
Pubbiz/Probiz Ltd. ﬁti.
15
A Randomized Clinical Trial Comparing
Breakfast and Bedtime Administration of
Insulin Glargine in Children and Adolescents
with Type 1 Diabetes
Damla Gökﬂen-ﬁimﬂek, Baﬂak Y›ld›z, Gülgün Asar, ﬁükran Darcan
Ege University, Faculty of Medicine, Pediatric Endocrinology and Metabolism Unit, ‹zmir, Turkey
ORIGINAL
ARTICLE
Keywords:
Glargine insulin, type 1
diabetes, children,
adolescents
Received: August 1, 2008
Accepted: September 3, 2008
Corresponding Author:
Damla Göksen ﬁimﬂek
Ege Üniversitesi T›p Fakültesi
Pediatrik Endokrinoloji ve
Metabolizma BD 35100
Bornova-‹zmir-Turkey 
Tel: +90-232 388 63 66
Fax: +90-232 388 63 66
E-mail:
damla.goksen@ege.edu.tr
ABSTRACT
Background: Insulin glargine provides effective glycemic control when administered at
bedtime in adults.
Objective: This study aims to investigate whether insulin glargine is equally effective if
administered in the morning or at bedtime in combination with preprandial anologue insulin.
Methods: Twenty-eight patients that have been treated with an intensified insulin regimen
for at least one year were randomized to insulin glargine injection at breakfast (06:00-09:00)
(12 patients) or bedtime (21:00-24:00) (16 patients), plus meal-time anologue insulin in the
two groups. Glucose data from each day were analyzed at four different times: between 9:00
and 21:00 (t1), between 21:00 and 24:00 (t2), between 24:00 and 04:00 (t3),04:00 and
09:00 (t4) by the Minimed continuous glucose monitoring system. 
Results: Baseline characteristics were similar in the two groups. The sensor values were lower
before breakfast in the bedtime group (180.5±49.0 vs 223.8±47.3 mg/dl, p=0.03). There were
13.7 events.patient-1.day-1 in the bedtime group and 6.9 events.patient-1.day-1 in the
breakfast group in which glucose levels fell below 60 mg/dl (p=0.3). There were 121.6
events.patient-1.day-1 in the bedtime group and 162.4 events.patient-1.day-1 in the breakfast
group in which glucose levels exceeded 180 mg/dl (p=0.05). Nighttime hypoglycemia only
reached to a statistical significance between the two groups between 24:00 and 04:00. There
were no significant correlations between the duration of nocturnal hypoglycemia, age,
duration of diabetes, gender and HbA1c levels. 
Conclusion: Breakfast group is hyperglycemic during the day and hyperglycemia starts in the
morning at 04:00. There is no significant difference in the frequency or duration of hypo/hyper-
glycemia during the day and night irrespective of the timing of glargine injection except pre-
breakfast levels are significantly better in the bedtime group and hypoglycemia occurs between
midnight and 04:00 in the bedtime group.
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useINTRODUCTION
The time action profile of insulin glargine
has been demonstrated to provide a contin-
uous, smooth supply of insulin with no pro-
nounced peak over a 24 h period. This
unique action profile enables individual tai-
loring of the timing of basal insulin action.(1)
In a combination regimen with prandial
insulin, insulin glargine provides equivalent
levels of glycemic control and reduces the
frequency of hypoglycemia when compared
to NPH insulin.(2, 3, 4) There is only one
adult and one pediatric study comparing the
regimen of intensive basal insulin supple-
mentation with once daily glargine adminis-
tration at breakfast versus bedtime.(5, 6)
The aim of this study was to investigate
whether insulin glargine is equally effective
if administered in the morning or at bedtime
in combination with preprandial insulin ana-
logue on glycemic control and nocturnal
hypo/hyperglycemia, based on blood glu-
cose values from 24 hour glucose monitor-
ization system (CGMS) (Medtronic Minimed
[Northridge CA]) on the 12th week when the
metabolic control had been stabilized. 
MATERIALS AND METHODS
Patient Population
A total of 28 patients with type 1 diabetes
were recruited for this study during routine
outpatient visits. The mean age of the sub-
jects were 12.2±4.3 years, (4.8-20.8 years).
Patients had a mean duration of diabetes of
4.8±3.5 years and a mean HbA1c of 8.7±1.9%.
Study Protocol
In this open label, randomized study, 28
patients (14 females, 14 males) that have
been treated with an intensified insulin regi-
men (neutral protamine Hagedorn
(NPH)+Regular insulin (R)/or NPH+Lispro/
aspart) for at least one year were random-
ized to insulin glargine (Lantus Aventis
Pharma) injection at breakfast-time (06:00-
09:00) (6 females, 6 males), or at bedtime
(21:00-24:00) (8 females, 8 males), each plus
meal-time rapid-acting insulin analogue (16
bedtime insulin, 12 breakfast insulin) after a
2 weeks screening phase where patients
continued their usual insulin regimen and
were encouraged to strive for optimal
glycemic control. Total daily basal insulin
glargine dose was calculated as 45% of the
total dose. Basal insulin was titrated by the
patient based on home self monitored glu-
cose measurements (SMBG) according to the
predefined premeal blood glucose of 80-120
mg/dL. Short acting insulin anologue was
titrated individually as necessary, aiming to
reach a postprandial glucose of no more
than 140 mg/dL.
CGMS was performed at the end of the
12th week of insulin glargine treatment. At
that time the patients came in for an outpa-
tient visit for sensor insertion and they were
instructed to keep detailed logs during this
period and record events, insulin dosage and
exercise and were trained how to use CGMS.
CGMS sensor replacement was done by a
certified diabetes nurse. Calibration of the
sensor was accomplished by the protocol
established as outlined in the Minimed CGMS
manual. At the completion of the CGMS peri-
od the system was returned and the data
were downloaded and converted into glu-
cose levels using Minimed Solution software
version 3.0. Logbooks were also analyzed to
determine finger stick blood glucose levels. 
Weight and height were measured by
standard methods and body mass index
(BMI) was calculated accordingly (kg/m2)
and expressed as standard deviation score
(SDS) according to Cole et al.(7)
Data Analyses
Glucose data from each day were ana-
lyzed at four different time periods: between
9:00 and 21:00 (t1), between 21:00 and 24:00
(t2), between 24:00 and 04:00 (t3), 04:00 and
09:00 (t4). 
Glycemic excursions were defined as
hypoglycemia <60 mg/dL and hyperglycemia
as any sensor value >180 mg/dL.
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CGMS monitor to obtain correlation coeffi-
cients between the SMBG and the CGMS val-
ues. We analyzed the data if 288 sensor val-
ues per 24 h were available. Average glu-
cose concentration per 24 h, average glu-
cose concentration during the time periods
given above, as well as number of excur-
sions, time and area under the glucose curve
(AUC) above 180 mg/dL and below 60
mg/dL were calculated from the CGMS data.
Additionally, average glucose concentration
per 24 hour was calculated from the results
of the standardized self monitoring of blood
glucose performed by the patients. The fol-
lowing cutoff criteria for optimal accuracy
were adhered to: the correlation coefficient
between the sensor and the meter readings
was above the cutoff point of 0.79 and a
mean absolute difference (MAD) of sensor
and meter readings was below 28%.
Glycated hemoglobin (HbA1c) was meas-
ured by high performance liquid chromatog-
raphy at onset and at 12th week of the study.
SPSS (version 11.0) statistical software
was used for analyses. All values are pre-
sented as mean±SD. Nonparametric tests
were used for comparison between the
mean values. P values of less than 0.05 were
considered significant.
All patients and families were informed
about the study and consents were obtained. 
RESULTS
Baseline characteristics of the patients
were similar in the two groups (Table 1). All
the patients completed 12 weeks of insulin
glargine therapy. During home use 26 of the
28 patients used CGMS for >60 h, which
included three overnight profiles. In the two
children the sensor was disconnected. In
one of the children the first sensor had to be
replaced in the first day. The system was
well tolerated by all subjects. 
An insignificant reduction of mean HbA1c
from baseline to end point (end of 12 weeks)
occurred in both of the groups (Table 2).
Overall glycemic control
The overall mean of the SMBG levels
obtained by the subjects before meals during
the three days of sensor use was 179.3±35.5
and 197.2±29.6 mg/dL in the bedtime and
breakfast group respectively. The average of
the sensor readings obtained during the day
and night over the entire 3 day period were
similar (187±43.4 vs 204.0±23.4 mg/dL
respectively) (Table 3).
There were 13.7 events.patient-1.day-1 in the
bedtime group and 6.9 events.patient-1.day-1 in
the breakfast group in which sensor glucose
levels fell below 60 mg/dL all through the day
(p=0.3). 
There were 121.6 events.patient-1.day-1 in
the bedtime group and 162.4 events.
patient-1.day-1 in the breakfast group in which
sensor glucose levels exceeded the target of
180 mg/dL throughout the day (p=0.05).
Daytime glycemic control (09:00 to 21:00)
The pre and post meal sensor values
tended to be lower before breakfast in the
bedtime group (Table 4). Peak postprandi-
ﬁimﬂek DG. et al
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Table 1: Characteristics of the two groups
Characteristics Breakfast group Bedtime group p
Age (year) 11.7±4.8 12.7±4.0 0.4
Duration of 5.8±4.0 4.1±3.0 0.3
Diabetes (year) 
BMI SDS 0.9±1.6 1.1±2.2 0.8
HbA1c (%) 8.7±2.1 8.7±1.7 0.4
Table 2: HbA1c at baseline and at 12 weeks in two groups
HbA1c (%) p
Baseline 12 weeks
Breakfast group 8.7±2.1 8.2±0.9 0,4
Bedtime group 8.7±1.7 8.4±1.5 0,3
Table 3: Sensor and meter variables throughout 3 days
Breakfast group Bedtime group p
Sensor Variables
Average (mg/dL)      204.0±23.4 187±43.4 0.1
Meter Variables
Average (mg/dL)      197.16±29.6 179.3±35.5 0.1al values were near our target range (180
mg/dL).
There were 8.5 events.patient-1.day-1 in
the bedtime group and 0.9 events.patient-1.
day-1 in the breakfast group in which sensor
glucose levels fell below 60 mg/dL between
09:00 and 21:00 (p=0.3). Sensor glucose lev-
els were below 60 mg/dL for a mean of
127.5±354.6 and 13.8±23.5 min/daytime for
the bedtime and breakfast group respective-
ly (p=0.2).
There were 54.2 events.patient-1.day-1 in
the bedtime group and 77.5 events.patient-
1.day-1 in the breakfast group in which sen-
sor glucose levels exceeded the target of 180
mg/dl between 09:00 and 21:00 (p=0.05).
Sensor glucose levels were >180 mg/dl for a
mean of 83.3±149.4 and 90.8±65.9 min/day-
time for the bedtime and breakfast group
respectively (p=0.9).
Nighttime (21:00 to 09:00) glycemic control
When glucose levels from all nocturnal
profiles were analyzed, sensor glucose levels
were below 60 mg/dl for a mean of
28.4±49.8 and 30.2±76.0 min/night for the
bedtime and breakfast group respectively
(p=0.9).
Nighttime hypoglycemia did not reach to
a statistical significance between the two
groups except in the time interval 2 (t2). The
frequency of hypoglycemia during t2 was
2.4 events.patient-1.night-1 vs 0.0 (p=0.005).
The frequency of hyperglycemia did not
reach to a significant difference between the
two groups in none of the time periods dur-
ing night.
The duration of hyper- and hypo-
glycemic periods throughout the day are
given in Table 5.
43.8% of the bedtime group had night-
time hypoglycemia whereas 33.3% of the
breakfast group had nocturnal hypo-
glycemia. There were no significant correla-
tions between the duration of nocturnal
hypoglycemia and patient age, duration of
diabetes and HbA1c levels. Similarly gender
did not significantly affect nocturnal hypo-
glycemia duration.
DISCUSSION
The aim of this study was to investigate
whether insulin glargine is equally effective
if administered in the morning or at bedtime
in combination with preprandial insulin
anologue on glycemic control and nocturnal
hypo/hyperglycemia; based on blood glu-
cose values from 24 hour glucose monitor-
ization system. This data shows that there
was no significant difference in the frequen-
cy or duration of hypo/hyperglycemia dur-
ing the day and night irrespective of the tim-
ing of glargine injection. Breakfast glargine
protected only from hypoglycemia occurring
in between 24:00 and 04:00. Breakfast group
was hyperglycemic during the day and
hyperglycemia started in the morning at
04:00. 
Minor reductions in HbA1c after 12
weeks of treatment were noted in both of
the groups as shown by Hamann et al(5) in
type 1 diabetics aged 18-68 years at the end
of 24 weeks. Karaguzel et al(6) had shown
significant reduction in HbA1c at the end of
six months of therapy with insulin glargine
only in the breakfast group. In poorly con-
trolled children and adolescents insulin
glargine at lunch time at the end of six
months of therapy showed a statistically sig-
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Table 4: Pre and post meal sensor values
Breakfast Lunch Dinner
Pre Post Pre Post Pre Post
Bedtime group (mg/dL) 180.5±49.0 184.2±59.4 177.5±77.6 180.0±45.6 185.0±75.2 189.4±48.9
Breakfast group (mg/dL) 223.8±47.3 191.3±55.3 191.3±55.3 199.2±71.3 187.8±45.6 179.7±47.1
p 0.03 0.01 0.3 0.6 0.6 0.4nificant drop in HbA1c.(8) In twenty-six ado-
lescents who have received 4 months of
bedtime insulin glargine with pre-meal
insulin lispro and 4 months of bedtime NPH
with pre-meal regular insulin fasting glucose
levels were lower on the glargine regimen,
but the hemoglobin A1c level was not statis-
tically different (8.7 vs. 9.1%).(9)
Studies have shown lower rate of noctur-
nal hypoglycemic events in patients with
type 1 diabetes on basal bolus regimen
involving insulin glargine as the basal substi-
tution given at bedtime compared with NPH
insulin.(10, 11)
Hypoglycemic events/patient/day betwe-
en the two groups were not different. A
slightly higher rate of hypoglycemic events
was found in the bedtime group during the
daytime. Although it has been stated that the
time action profile of glargine can decrease
the risk of nocturnal hypoglycemia and
should be given preferentially at bedtime(5)
there was a difference in the incidence of
nocturnal hypoglycemia in time interval t3
between the bedtime and breakfast group
(2.4 events.patient-1.night-1 vs. 0). Hamann
et al(5) reported that the incidences of total
symptomatic and severe hypoglycemia did
not differ between dinner, bedtime and
breakfast glargine insulin groups however
nocturnal hypoglycemia occurred in signifi-
cantly fewer patients in the breakfast group
compared with the dinner and bedtime
groups. In the study of Karagüzel et al(6) the
administration of once daily insulin glargine
at breakfast or bedtime was associated with
a decreased risk of all type of hypoglycemic
events. An insignificant increase of nocturnal
hypoglycemia during the time interval t1 in
the breakfast group could be due to incor-
rect adjustments of premeal insulin during
dinner since this time interval corresponds
to post meal.
The results of this study demonstrate that
insulin glargine in combination with insulin
lispro/aspart is equally effective on glycemic
control whether it is injected once daily
before breakfast or at bedtime in type 1 dia-
betic adolescents and children. There is no
significant difference in the frequency or
duration of hypo- and hyperglycemia during
the day and night irrespective of the timing
of glargine injection except pre breakfast
levels are significantly better in the bedtime
group and hypoglycemia occurs in between
midnight and 04:00 in the bedtime group. 
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